SEC Form 4 · accession 0001193125-26-271074
FATE THERAPEUTICS INC · FATE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matt Abernethy
Director
Period of report
Jun 12, 2026
Accepted (ET)
Jun 15, 2026 · 4:07 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001434316
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $2.06 | Jun 12, 2026 | A | 87,900 | A | — | Jun 12, 2036 | Common Stock | 87,900 | 87,900 | D |
Explanation of responses
- F1This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.
- F2The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.